Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.2952W HIGH $5.08
Volume
186.74 K
Value Traded
1.49 M
Short % Float
11.44%
+5.17%Week
-8.39%1 Month
-13.05%3 Month
+4.58%6 Month
-85.15%5 Year
-81.13%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
240.47 M
EPS (TTM)
-0.23
P/E Ratio
-
Ent. Value
66.53 M
Total Shares
63.70 M
Float Shares
61.45 M
Insiders
3.53%
Institutions
79.91%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
MGNX Catalyst Timeline
Dated clinical, regulatory and corporate events for MacroGenics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MacroGenics, Inc.
957Total events
15Upcoming
185Tier-1 (high impact)
2013 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Milestone PaymentCorporate
MacroGenics achieves $10 million milestone from Gilead's exercise of option to license preclinical bispecific program
▲Partnership / LicenseCorporate
Gilead exercised option to license preclinical bispecific program under 2022 collaboration agreement
▲Enrollment MilestoneMGC026Trial
Met pre-specified Stage 1 response threshold in SCCHN cohort; enrolling Stage 2
squamous cell carcinoma of the head and neck (SCCHN)source ↗
●Enrollment UpdateMGC026Trial
Total of 74 patients enrolled across dose escalation and cohort expansion as of July 8, 2026
advanced solid tumorssource ↗
▲AcquisitionCorporate
MacroGenics completes sale of GMP manufacturing operations to Bora Pharmaceuticals
◆Restructuring LayoffsCorporate
Corporate restructuring: ~140 employees to transfer to Bora, additional reductions, ~135 employees expected post-closing
▲Trial InitiationMGC030Trial
First patient expected to be dosed in Phase 1 study of MGC030 in Q3 2026
solid tumorssource ↗
▲Milestone PaymentCorporate
Payment of $24.5 million regulatory milestone from Sanofi expected in Q3 2026
▲FDA ApprovalTZIELDApprovedFDA Decision
FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children aged 8-17 with stage 3 T1D
stage 3 type 1 diabetessource ↗
▲Milestone PaymentTZIELDApprovedCorporate
MacroGenics to receive $24.5 million regulatory milestone payment from Sanofi following FDA approval
type 1 diabetessource ↗
▲FDA ApprovalTZIELDApprovedFDA Decision
FDA approved TZIELD to delay onset of Stage 3 T1D in adults
stage 3 type 1 diabetessource ↗
◆Oral PresentationPresentation
MacroGenics President and CEO to participate in fireside chat at Stifel 2026 Virtual Targeted Oncology Forum
▼Program DiscontinuationLorigerlimabCorporate
Discontinuation of development in PROC indication
high-grade serous and platinum-resistant ovarian cancersource ↗
▲Partnership / LicenseZYNYZApprovedCorporate
Expanded ZYNYZ royalty purchase agreement with Sagard
cancersource ↗
▲Partnership / LicenseZYNYZApprovedCorporate
Expanded ZYNYZ royalty monetization with Sagard Healthcare Partners
▲Clinical Hold LiftedLorigerlimabIND
FDA removes partial clinical hold on LINNET study
gynecologic cancerssource ↗
◆Enrollment UpdateLorigerlimabTrial
Plan to resume enrollment in LINNET study after partial clinical hold lifted
gynecologic cancerssource ↗
▲FDA ApprovalTZIELDApprovedFDA Decision
FDA expanded indication of TZIELD to children aged 1 year and above with stage 2 T1D
stage 2 type 1 diabetessource ↗
◆Timing GuidanceLorigerlimabPresentation
Mid-2026 program update for lorigerlimab
gynecologic cancerssource ↗
◆Topline ReadoutLorigerlimabClinical Data
Lorigerlimab Phase 2 LINNET study update
platinum-resistant ovarian cancer or clear cell gynecologic cancersource ↗
▲Milestone PaymentCorporate
Earned $24.5 million regulatory milestone from Sanofi related to U.S. approval of TZIELD
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
TD Cowen 46th Annual Health Care Conference presentation and fireside chat
▼Partial Clinical HoldLorigerlimabIND
FDA placed partial clinical hold on LINNET study of lorigerlimab
gynecologic cancerssource ↗
▼Enrollment PausedLorigerlimabTrial
Temporary pause in enrollment of new participants in LINNET trial due to safety events
gynecologic cancerssource ↗
▲Development Candidate NominationMGD032Preclinical
MGD032 nominated as development candidate and advancing in IND-enabling studies
undisclosed targetsource ↗
◆Oral PresentationPresentation
MacroGenics President and CEO to participate in fireside chat at 8th Annual Evercore Healthcare Conference
◆Oral PresentationPresentation
MacroGenics President and CEO to participate in fireside chat at Stifel 2025 Healthcare Conference
▲Partnership / LicenseCorporate
Secured $75 million in additional non-dilutive partnership payments expected in Q4 2025
●Dose Finding UpdateMGC026Trial
Dose escalation completed in Q4 2025; 7.5 mg/kg q3W selected for expansion
advanced solid tumorssource ↗
◆Oral PresentationPresentation
MacroGenics President & CEO to present at H.C. Wainwright 27th Annual Global Investment Conference
▲Partnership / LicenseCorporate
Extended relationship with Gilead to include a preclinical T-cell engager program
Past FDA Catalysts and PDUFA Decisions
How MGNX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | MGC030 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C51 / 100
Pipeline Score
$401M
Pipeline Value
$123M
Commercial Value
Undervalued
Valuation Signal
18
Drugs Scored
3.7x
rNPV / MCap
Top 16%
Micro Cap(rank 106 of 658)
Percentile Rank
MacroGenics, Inc. carries a moderate pipeline score (51/100), with $3.9B risk-adjusted pipeline value, led by MGC018 in Extensive-stage Small-cell Lung Cancer (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026) Revenue $122.5M x 1.0 = $123M
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MGC018 Small moleculeNCT06227546 | Extensive-stage Small-cell Lung Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 9 | May 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every MGNX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| vobramitamab duocarmazine | metastatic castration-resistant prostate cancer | Phase 2 | 2024-09-16 | 2.0 mg/kg cohort r PFS: 69%; 2.7 mg/kg cohort r PFS: 70%Read More | MacroGenics Announces Updated Efficacy Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bonvini EzioOfficer (Sr VP, Research & CSO) | Option | 8,000 193,799 held | $2.60 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MGNX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.1 % | 8.61 M | 1.86 M |
MGNX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MGNX ranks across every disease it competes in
Competitive Position is a premium feature
See how MGNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMGNX News
MGNXMacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MacroGenics, Inc. will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. CEO Eric Risser is set to present at 9:30 a.m. ET, with a webcast available for investors. The company focuses on developing antibody-based therapeutics for cancer treatment and maintains a strong pipeline through strategic collaborations.
Read more →MGNXMacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
MacroGenics reported strong financial results for Q2 2026, highlighting a cash position of $327 million and a streamlined operating model following the sale of its manufacturing operations. The company is advancing its clinical pipeline, with promising data presentations planned for MGC026 and lorigerlimab at ESMO 2026. The IND application for MGC030 has been cleared, with patient dosing expected soon.
Read more →MGNXMacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
MacroGenics, a biopharmaceutical company, has announced a significant milestone with Gilead Sciences exercising its option to license a preclinical bispecific program. This move has resulted in a $10 million milestone payment to MacroGenics, highlighting the potential of their innovative antibody-based therapeutics for cancer treatment. The collaboration reflects a strong partnership and confidence in MacroGenics' pipeline.
Read more →MGNX▼ -7.7%on this news
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
MacroGenics has provided a clinical update on its ongoing Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate. The study has successfully met the response threshold in the SCCHN cohort, allowing progression to Stage 2. Enrollment continues in other cohorts, with a total of 74 patients enrolled thus far and no significant safety issues reported.
Read more →MGNXMacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
MacroGenics has successfully completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million. This transaction includes the transfer of MacroGenics' manufacturing site and warehouse, along with the hiring of around 140 employees by Bora. Additionally, a supply agreement has been established to support MacroGenics' internal pipeline.
Read more →MGNXMacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
MacroGenics announced it will receive a $24.5 million milestone payment from Sanofi following the FDA's accelerated approval of TZIELD for delaying insulin decline in children with type 1 diabetes. This approval enhances TZIELD's role as a disease-modifying therapy. The company is also eligible for up to $305 million in additional payments.
Read more →MGNX▲ +20.6%on this news· ran to +31% by day 3
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
MacroGenics, Inc. has announced that its President and CEO, Eric Risser, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum. The event is scheduled for May 20, 2026, at 10:30 a.m. ET. Investors can access a webcast of the presentation on the company's website, which will also archive the presentation for 30 days post-event. This participation highlights MacroGenics' focus on developing innovative antibody-based therapeutics for cancer treatment.
Read more →MGNXMacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
MacroGenics reported its Q1 2026 financial results, highlighting a strategic divestiture of its manufacturing operations to enhance focus on drug discovery. The company anticipates up to $202.5 million from this and royalty monetization, supporting its pipeline and extending its cash runway through 2028. Despite a net loss, the ADC pipeline remains promising with several upcoming milestones.
Read more →MGNX▲ +19.3%on this news· ran to +44% by day 3shared move
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
MacroGenics has agreed to sell its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million. The deal includes the transfer of a manufacturing site and personnel, allowing MacroGenics to focus on its innovative pipeline. Bora plans to integrate the operations into its North American biologics strategy, ensuring continued service for existing clients.
Read more →MGNXMacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
MacroGenics has expanded its royalty purchase agreement with Sagard Healthcare Partners, receiving a $60 million upfront payment and potential future milestone payments based on ZYNYZ sales. ZYNYZ, a PD-1 inhibitor, is indicated for treating specific types of cancer. The agreement allows MacroGenics to retain other economic interests related to ZYNYZ.
Read more →MGNXMacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ Royalty Purchase Agreement
MacroGenics, Inc. has entered into an expanded royalty purchase agreement with Sagard Healthcare Partners, receiving an upfront payment of $60 million and the potential for an additional sales-based milestone of $20 million. This agreement pertains to future global net sales of its PD-1 inhibitor, ZYNYZ. The firm retains its economic interests in ZYNYZ, including development and regulatory milestones, while Sagard aims to recover its investment through sales. MacroGenics views this deal as a reinforcement of ZYNYZ's strategic importance.
Read more →MGNXFDA Removes Partial Clinical Hold on MacroGenics' LINNET Study Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers
MacroGenics, Inc. has announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study assessing lorigerlimab in patients with gynecologic cancers. The study aims to enroll up to approximately 60 participants who have platinum-resistant ovarian cancer or clear cell gynecologic cancer. New participants will be enrolled under a revised protocol with additional risk mitigation for potential toxicities. The company continues to prepare for a mid-2026 program update regarding this clinical trial.
Read more →MGNX▲ +5.8%on this news· ran to +54% by day 1
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
MacroGenics reported its 2025 financial results, revealing a cash balance of $189.9 million which supports operating activities into late 2027. The company outlined key upcoming data disclosures, including initial results from Phase 1 trials of MGC026 and MGC028 expected in mid-2026 and the second half of 2026, respectively. Additionally, there is an IND submission planned for MGC030 in Q3 2026. However, the company is currently facing a partial clinical hold on its LINNET study, which is under review by the FDA.
Read more →MGNXMacroGenics to Participate in Upcoming March 2026 Investor Conferences
MacroGenics, Inc. has announced its participation in several investor conferences scheduled for March 2026. The company's management team will present, and webcasts of these presentations will be available on their website. This initiative reflects MacroGenics' focus on engaging with investors and promoting its innovative antibody-based therapeutics for cancer treatment.
Read more →MGNXMacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. has announced its participation in several upcoming investor conferences throughout March 2026, including events in Boston and Miami. CEO Eric Risser will engage in hybrid presentations and fireside chats designed to connect with investors. The conferences are an opportunity for MacroGenics to showcase its innovative antibody-based therapeutics and strengthen relationships within the investor community. Webcasts of these presentations will be available for public access on the company's website.
Read more →MGNXMacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
MacroGenics has announced a partial clinical hold on its Phase 2 LINNET study of lorigerlimab due to safety concerns. The FDA's action follows reports of serious adverse events among participants, including Grade 4 thrombocytopenia and myocarditis. While new patient enrollment is halted, existing participants may continue treatment. The company is working closely with the FDA to lift the hold.
Read more →MGNXMacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer
MacroGenics, Inc. announced a partial clinical hold by the FDA on its LINNET study of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4 in gynecologic cancers. The hold was prompted by recent severe safety events involving study participants, including Grade 4 adverse effects. While current participants may continue treatment, no new enrollments will occur until the hold is lifted. MacroGenics expressed its commitment to patient safety and intends to work with the FDA to resolve the issue promptly.
Read more →MGNXMacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
MacroGenics, Inc. announced its participation in the 8th Annual Evercore Healthcare Conference, scheduled for December 4, 2025, in Miami, FL. Eric Risser, the President and CEO, will lead a fireside chat at the event starting at 7:55 am ET. This appearance will be accessible via a webcast on the company's Investor Relations page, ensuring that interested parties can follow the discussion. MacroGenics aims to continue showcasing its innovative cancer therapies at major industry events.
Read more →MGNX▲ +8.8%on this news
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
MacroGenics reported its third quarter 2025 financial results, highlighting a $75 million non-dilutive partnership payment. The company has decided to halt development of lorigerlimab for prostate cancer but will continue its exploration in ovarian and gynecologic cancers. Additionally, MacroGenics is advancing its ADC programs and has initiated Phase 1 expansion cohorts for MGC026.
Read more →MGNXMacroGenics to Participate in the Stifel 2025 Healthcare Conference
MacroGenics, Inc. announced its participation in the Stifel 2025 Healthcare Conference, where CEO Eric Risser will engage in a fireside chat. The event is scheduled for November 13, 2025, in New York City. A webcast of the presentation will be available on the company's website, with an archived replay for 30 days.
Read more →About MacroGenics, Inc.
Headquarters9704 MEDICAL CENTER DRIVE, Rockville, MD, 20850
BIOPHARMAWATCH ELITE PLUS
Trade the next MGNX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime